CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
Alisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00830518
NCT00830518Phase 2Completed
CompareCT.gov

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Millennium Pharmaceuticals, Inc.·interventional·Posted Jan 28, 2009·Updated May 11, 2018

In Brief

A Phase 2 clinical trial evaluating Alisertib for Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome. Completed, enrolled 57 participants across 1 site.

Detailed Summary

This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 28, 2009
Enrollment StartFeb 10, 2009
Primary CompletionFeb 2, 2010
Study CompletionJul 4, 2011
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 17.4 years ago

Interventions

Alisertibdrug

Alisertib capsules